'We are grateful to the BXLS VI investors for their strong support of our strategies and the firm's enduring conviction in the life sciences,' said Nicholas Galakatos, Global Head of Blackstone Life Sciences. The platform has supported 34 regulatory approvals of medicines and medical devices, including high-profile therapies and technologies, highlighting its role as a strategic capital provider in the sector. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today.
learn more
